Statement of Policy Intent sets out initial thinking on a new Early Access service to help patients benefit sooner from innovative medical devices that address unmet clinical needs.
Similar Posts
Updated guidance on the management of the recalled Endologix Nellix EndoVascular Aneurysm Sealing (EVAS) System (DSI/2025/004)
The MHRA provides an update to previous guidance on the management of patients treated with the recalled Endologix Nellix EVAS System to reflect revised recommendations. All implanted patients in the UK with this device should be identified and appropriate action taken.
Professor Henrietta Hughes: Putting Patient Safety at the Heart of Regulatory Innovation
Professor Henrietta Hughes reflects on how MHRA strategy must prioritise patient safety via listening to lived experiences, fostering collaboration & innovation.
Festive foods and your medicines: MHRA shares advice to help you stay safe this winter
This holiday season, the MHRA is reminding people that some common festive foods can interact with medicines, altering how well they work or increasing the risk of side effects.
MHRA smashes major illicit weight loss medicine production facility in record seizure
MHRA strikes massive blow to organised criminal gang in world’s biggest illegal weight loss jabs raid.
Breast implants – patient perception of risk research
Information for patients, public and healthcare professionals
Class 3 Medicines Recall: Sun Pharmaceutical Industries Limited, Atorvastatin 20mg and 80mg Film-coated Tablets, EL(25)A/48
Sun Pharma UK Limited are recalling the batches of tablets specified in the table as a precautionary measure due to failing dissolution test results reported during ongoing stability studies.